Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Percutaneous Coronary Intervention | 82 | 2024 | 475 | 8.410 |
Why?
|
Coronary Angiography | 43 | 2024 | 341 | 4.350 |
Why?
|
Myocardial Infarction | 49 | 2023 | 1031 | 3.620 |
Why?
|
Registries | 72 | 2024 | 1916 | 3.500 |
Why?
|
Coronary Artery Disease | 29 | 2024 | 695 | 2.780 |
Why?
|
Transcatheter Aortic Valve Replacement | 11 | 2024 | 168 | 2.570 |
Why?
|
Aortic Valve Stenosis | 12 | 2024 | 291 | 2.310 |
Why?
|
Cardiac Catheterization | 25 | 2024 | 583 | 2.190 |
Why?
|
Angioplasty, Balloon, Coronary | 25 | 2014 | 152 | 2.170 |
Why?
|
Cardiology | 12 | 2022 | 281 | 1.580 |
Why?
|
Hemorrhage | 23 | 2024 | 658 | 1.540 |
Why?
|
Radial Artery | 17 | 2022 | 68 | 1.480 |
Why?
|
Hospital Mortality | 30 | 2024 | 853 | 1.290 |
Why?
|
Drug-Eluting Stents | 13 | 2019 | 65 | 1.250 |
Why?
|
Cardiovascular Diseases | 13 | 2023 | 2013 | 1.220 |
Why?
|
Acute Coronary Syndrome | 11 | 2024 | 267 | 1.170 |
Why?
|
Ultrasonography, Interventional | 7 | 2015 | 139 | 1.080 |
Why?
|
Femoral Artery | 14 | 2022 | 176 | 1.070 |
Why?
|
Aged | 122 | 2024 | 22035 | 1.040 |
Why?
|
Treatment Outcome | 79 | 2024 | 10239 | 1.020 |
Why?
|
Platelet Aggregation Inhibitors | 14 | 2019 | 453 | 1.020 |
Why?
|
Heart Valve Prosthesis | 4 | 2021 | 132 | 0.990 |
Why?
|
Contrast Media | 9 | 2024 | 387 | 0.990 |
Why?
|
United States | 86 | 2024 | 13975 | 0.980 |
Why?
|
Ticlopidine | 7 | 2016 | 55 | 0.940 |
Why?
|
Pacemaker, Artificial | 19 | 2018 | 115 | 0.900 |
Why?
|
Postoperative Complications | 13 | 2024 | 2494 | 0.890 |
Why?
|
Coronary Artery Bypass | 11 | 2021 | 224 | 0.880 |
Why?
|
Influenza Pandemic, 1918-1919 | 1 | 2023 | 1 | 0.860 |
Why?
|
Coronary Stenosis | 8 | 2014 | 43 | 0.860 |
Why?
|
Aortic Valve | 9 | 2024 | 425 | 0.830 |
Why?
|
Imaging, Three-Dimensional | 13 | 2016 | 559 | 0.830 |
Why?
|
Catheterization, Peripheral | 7 | 2022 | 104 | 0.820 |
Why?
|
Humans | 207 | 2024 | 128896 | 0.800 |
Why?
|
Coronary Vessels | 13 | 2019 | 252 | 0.790 |
Why?
|
Purinergic P2Y Receptor Antagonists | 7 | 2019 | 67 | 0.770 |
Why?
|
Risk Factors | 49 | 2024 | 9792 | 0.770 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2023 | 145 | 0.760 |
Why?
|
Stents | 15 | 2016 | 518 | 0.750 |
Why?
|
Shock, Cardiogenic | 10 | 2023 | 61 | 0.740 |
Why?
|
Electrocardiography | 21 | 2020 | 602 | 0.720 |
Why?
|
Time Factors | 38 | 2024 | 6568 | 0.710 |
Why?
|
Acute Kidney Injury | 5 | 2024 | 786 | 0.700 |
Why?
|
Middle Aged | 99 | 2024 | 30977 | 0.700 |
Why?
|
Computer Simulation | 7 | 2014 | 943 | 0.670 |
Why?
|
Hospitals | 10 | 2022 | 628 | 0.670 |
Why?
|
Male | 135 | 2024 | 63146 | 0.660 |
Why?
|
Radiography, Interventional | 8 | 2019 | 114 | 0.650 |
Why?
|
Female | 134 | 2024 | 68162 | 0.650 |
Why?
|
Risk Assessment | 26 | 2024 | 3286 | 0.630 |
Why?
|
Coronary Disease | 10 | 2012 | 389 | 0.620 |
Why?
|
Coronary Restenosis | 3 | 2013 | 20 | 0.600 |
Why?
|
ST Elevation Myocardial Infarction | 4 | 2023 | 52 | 0.570 |
Why?
|
Practice Patterns, Physicians' | 10 | 2019 | 1281 | 0.530 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2013 | 8 | 0.530 |
Why?
|
Myocardial Ischemia | 6 | 2013 | 254 | 0.530 |
Why?
|
Echocardiography, Three-Dimensional | 4 | 2019 | 53 | 0.520 |
Why?
|
Hospitals, High-Volume | 6 | 2021 | 40 | 0.520 |
Why?
|
Models, Cardiovascular | 3 | 2013 | 193 | 0.510 |
Why?
|
Follow-Up Studies | 29 | 2021 | 4917 | 0.510 |
Why?
|
Cardiac Pacing, Artificial | 13 | 2007 | 82 | 0.510 |
Why?
|
Graft Occlusion, Vascular | 4 | 2019 | 39 | 0.500 |
Why?
|
Aged, 80 and over | 38 | 2024 | 7050 | 0.490 |
Why?
|
Hospitals, Low-Volume | 5 | 2021 | 23 | 0.490 |
Why?
|
Allografts | 1 | 2015 | 138 | 0.470 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 9 | 2019 | 108 | 0.470 |
Why?
|
Medicare | 12 | 2021 | 734 | 0.470 |
Why?
|
Survival Rate | 12 | 2021 | 1884 | 0.470 |
Why?
|
Patient Readmission | 7 | 2024 | 674 | 0.460 |
Why?
|
Prasugrel Hydrochloride | 5 | 2016 | 22 | 0.460 |
Why?
|
Intra-Aortic Balloon Pumping | 4 | 2021 | 16 | 0.460 |
Why?
|
Fluoroscopy | 7 | 2021 | 167 | 0.450 |
Why?
|
Vascular Diseases | 2 | 2015 | 241 | 0.430 |
Why?
|
Time-to-Treatment | 4 | 2024 | 182 | 0.430 |
Why?
|
Heart Arrest | 4 | 2021 | 327 | 0.420 |
Why?
|
Computer-Assisted Instruction | 1 | 2013 | 60 | 0.420 |
Why?
|
Postoperative Hemorrhage | 4 | 2016 | 85 | 0.420 |
Why?
|
Heart Defects, Congenital | 4 | 2021 | 752 | 0.410 |
Why?
|
Quality Indicators, Health Care | 5 | 2021 | 299 | 0.410 |
Why?
|
Retrospective Studies | 38 | 2024 | 14546 | 0.410 |
Why?
|
Length of Stay | 7 | 2024 | 1126 | 0.410 |
Why?
|
Heart Valve Prosthesis Implantation | 4 | 2024 | 198 | 0.400 |
Why?
|
Coronary Thrombosis | 2 | 2012 | 25 | 0.400 |
Why?
|
Heart-Assist Devices | 4 | 2023 | 529 | 0.400 |
Why?
|
Decision Support Techniques | 6 | 2024 | 387 | 0.390 |
Why?
|
Patient Discharge | 6 | 2024 | 858 | 0.380 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2024 | 86 | 0.370 |
Why?
|
Heart Failure | 3 | 2023 | 2142 | 0.370 |
Why?
|
Teaching | 1 | 2013 | 209 | 0.370 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 361 | 0.360 |
Why?
|
Coronavirus Infections | 3 | 2020 | 355 | 0.350 |
Why?
|
Coronary Aneurysm | 1 | 2010 | 13 | 0.350 |
Why?
|
Heart Block | 8 | 2018 | 41 | 0.350 |
Why?
|
Embolic Protection Devices | 2 | 2024 | 13 | 0.340 |
Why?
|
Clinical Competence | 7 | 2017 | 1020 | 0.340 |
Why?
|
Echocardiography, Transesophageal | 4 | 2021 | 104 | 0.340 |
Why?
|
Anticoagulants | 6 | 2015 | 622 | 0.340 |
Why?
|
Arrhythmias, Cardiac | 7 | 2023 | 312 | 0.330 |
Why?
|
Hemostatic Techniques | 3 | 2020 | 46 | 0.330 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 1523 | 0.330 |
Why?
|
Endovascular Procedures | 3 | 2020 | 304 | 0.320 |
Why?
|
Image Enhancement | 2 | 2010 | 165 | 0.320 |
Why?
|
Education, Medical, Graduate | 1 | 2013 | 436 | 0.320 |
Why?
|
Peptide Fragments | 6 | 2020 | 694 | 0.320 |
Why?
|
Heart Transplantation | 1 | 2015 | 713 | 0.320 |
Why?
|
Databases, Factual | 6 | 2024 | 1289 | 0.310 |
Why?
|
Radiation Dosage | 7 | 2016 | 159 | 0.310 |
Why?
|
Predictive Value of Tests | 16 | 2020 | 1967 | 0.310 |
Why?
|
Veterans | 2 | 2019 | 1397 | 0.300 |
Why?
|
Hirudins | 6 | 2020 | 51 | 0.290 |
Why?
|
Cardiology Service, Hospital | 2 | 2020 | 27 | 0.290 |
Why?
|
Prospective Studies | 22 | 2024 | 7060 | 0.290 |
Why?
|
Patient Simulation | 1 | 2008 | 34 | 0.290 |
Why?
|
Myocardial Revascularization | 6 | 2016 | 70 | 0.280 |
Why?
|
Angioplasty | 2 | 2010 | 47 | 0.280 |
Why?
|
Incidence | 12 | 2020 | 2634 | 0.270 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2021 | 248 | 0.270 |
Why?
|
Quality Improvement | 5 | 2019 | 1101 | 0.270 |
Why?
|
Defibrillators, Implantable | 3 | 2022 | 295 | 0.270 |
Why?
|
Device Removal | 3 | 2005 | 140 | 0.270 |
Why?
|
Societies, Medical | 4 | 2020 | 760 | 0.260 |
Why?
|
Workload | 2 | 2019 | 154 | 0.260 |
Why?
|
Pandemics | 4 | 2023 | 1516 | 0.250 |
Why?
|
Electrocardiography, Ambulatory | 2 | 2019 | 58 | 0.250 |
Why?
|
Prognosis | 8 | 2024 | 3787 | 0.250 |
Why?
|
Propensity Score | 7 | 2020 | 262 | 0.250 |
Why?
|
Antithrombins | 4 | 2020 | 55 | 0.250 |
Why?
|
Drug Substitution | 2 | 2016 | 50 | 0.250 |
Why?
|
Advisory Committees | 2 | 2020 | 231 | 0.240 |
Why?
|
Comorbidity | 8 | 2019 | 1542 | 0.240 |
Why?
|
Radiographic Image Enhancement | 3 | 2006 | 58 | 0.240 |
Why?
|
American Heart Association | 3 | 2016 | 311 | 0.240 |
Why?
|
Odds Ratio | 10 | 2017 | 1019 | 0.230 |
Why?
|
Education, Medical | 1 | 2008 | 241 | 0.230 |
Why?
|
Heart Septum | 2 | 2015 | 28 | 0.230 |
Why?
|
Peripheral Vascular Diseases | 2 | 2019 | 104 | 0.230 |
Why?
|
Consensus | 4 | 2020 | 644 | 0.230 |
Why?
|
Thrombolytic Therapy | 3 | 2020 | 137 | 0.230 |
Why?
|
Angiography | 4 | 2021 | 199 | 0.220 |
Why?
|
Cardiologists | 2 | 2021 | 46 | 0.220 |
Why?
|
Comparative Effectiveness Research | 6 | 2016 | 151 | 0.220 |
Why?
|
Learning Curve | 2 | 2015 | 68 | 0.220 |
Why?
|
Kidney Diseases | 2 | 2023 | 366 | 0.220 |
Why?
|
Vascular Fistula | 1 | 2024 | 20 | 0.220 |
Why?
|
Certification | 2 | 2015 | 93 | 0.220 |
Why?
|
Healthcare Disparities | 3 | 2020 | 570 | 0.220 |
Why?
|
Algorithms | 8 | 2020 | 1626 | 0.220 |
Why?
|
Internship and Residency | 1 | 2013 | 1052 | 0.220 |
Why?
|
Aspirin | 3 | 2015 | 379 | 0.220 |
Why?
|
Heart Diseases | 3 | 2019 | 356 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 1366 | 0.220 |
Why?
|
Hypothermia, Induced | 1 | 2024 | 74 | 0.220 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 287 | 0.220 |
Why?
|
Sex Factors | 6 | 2019 | 1947 | 0.220 |
Why?
|
Stroke | 7 | 2024 | 1111 | 0.210 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2015 | 129 | 0.210 |
Why?
|
Myocardial Reperfusion | 2 | 2013 | 52 | 0.210 |
Why?
|
Betacoronavirus | 3 | 2020 | 266 | 0.210 |
Why?
|
Intraoperative Care | 2 | 2013 | 44 | 0.210 |
Why?
|
Research Design | 3 | 2022 | 1038 | 0.200 |
Why?
|
Cineangiography | 5 | 2009 | 16 | 0.200 |
Why?
|
Heart Injuries | 1 | 2023 | 39 | 0.200 |
Why?
|
Age Factors | 9 | 2020 | 3133 | 0.200 |
Why?
|
Enoxaparin | 2 | 2015 | 59 | 0.190 |
Why?
|
History, 20th Century | 1 | 2023 | 294 | 0.190 |
Why?
|
Severity of Illness Index | 12 | 2020 | 2767 | 0.190 |
Why?
|
Heart Ventricles | 6 | 2018 | 778 | 0.190 |
Why?
|
Multimodal Imaging | 2 | 2019 | 107 | 0.190 |
Why?
|
Guideline Adherence | 3 | 2015 | 526 | 0.190 |
Why?
|
Technology Transfer | 1 | 2021 | 12 | 0.190 |
Why?
|
Forecasting | 2 | 2022 | 363 | 0.190 |
Why?
|
Inpatients | 2 | 2024 | 456 | 0.190 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2019 | 561 | 0.190 |
Why?
|
Breast Neoplasms | 1 | 2013 | 2112 | 0.190 |
Why?
|
Reproducibility of Results | 9 | 2021 | 3042 | 0.180 |
Why?
|
Physicians | 3 | 2015 | 846 | 0.180 |
Why?
|
Longitudinal Studies | 10 | 2019 | 2668 | 0.180 |
Why?
|
Tachycardia, Ventricular | 2 | 2024 | 167 | 0.180 |
Why?
|
Retreatment | 3 | 2019 | 69 | 0.180 |
Why?
|
Surgicenters | 1 | 2020 | 6 | 0.180 |
Why?
|
Ischemia | 3 | 2009 | 396 | 0.180 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2021 | 281 | 0.170 |
Why?
|
Proportional Hazards Models | 8 | 2016 | 1221 | 0.170 |
Why?
|
Saphenous Vein | 3 | 2015 | 32 | 0.170 |
Why?
|
Manuals as Topic | 1 | 2020 | 14 | 0.170 |
Why?
|
Thrombosis | 3 | 2016 | 331 | 0.170 |
Why?
|
Septal Occluder Device | 2 | 2018 | 50 | 0.170 |
Why?
|
Assisted Circulation | 2 | 2021 | 25 | 0.170 |
Why?
|
Ethanol | 2 | 2015 | 577 | 0.170 |
Why?
|
Chi-Square Distribution | 6 | 2017 | 513 | 0.160 |
Why?
|
Rural Health Services | 1 | 2020 | 109 | 0.160 |
Why?
|
Absorbable Implants | 1 | 2019 | 36 | 0.160 |
Why?
|
Logistic Models | 8 | 2017 | 1963 | 0.160 |
Why?
|
Popliteal Artery | 2 | 2009 | 60 | 0.160 |
Why?
|
Angina Pectoris | 1 | 2019 | 68 | 0.160 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2019 | 43 | 0.160 |
Why?
|
Atrioventricular Block | 1 | 2019 | 35 | 0.160 |
Why?
|
Electrodes, Implanted | 5 | 1999 | 103 | 0.160 |
Why?
|
Infection Control | 1 | 2020 | 138 | 0.160 |
Why?
|
Atrial Fibrillation | 3 | 2007 | 370 | 0.150 |
Why?
|
Medicaid | 2 | 2013 | 445 | 0.150 |
Why?
|
Models, Anatomic | 2 | 2009 | 94 | 0.150 |
Why?
|
Vascular System Injuries | 1 | 2019 | 73 | 0.150 |
Why?
|
Health Care Costs | 2 | 2019 | 404 | 0.150 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2015 | 739 | 0.150 |
Why?
|
Quality of Health Care | 2 | 2016 | 610 | 0.150 |
Why?
|
Recombinant Proteins | 8 | 2020 | 1304 | 0.150 |
Why?
|
Cohort Studies | 11 | 2023 | 5394 | 0.140 |
Why?
|
Myocardium | 1 | 2023 | 981 | 0.140 |
Why?
|
Creatinine | 4 | 2024 | 485 | 0.140 |
Why?
|
Rotation | 5 | 2011 | 118 | 0.140 |
Why?
|
Subacute Care | 1 | 2018 | 74 | 0.140 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 131 | 0.140 |
Why?
|
Vascular Surgical Procedures | 3 | 2009 | 295 | 0.140 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2016 | 8 | 0.140 |
Why?
|
Tissue Scaffolds | 1 | 2019 | 193 | 0.140 |
Why?
|
Leg | 2 | 2009 | 241 | 0.130 |
Why?
|
Angioplasty, Balloon | 2 | 2007 | 90 | 0.130 |
Why?
|
Aortography | 1 | 2016 | 51 | 0.130 |
Why?
|
Equipment Design | 7 | 2014 | 522 | 0.130 |
Why?
|
Multidetector Computed Tomography | 1 | 2016 | 33 | 0.130 |
Why?
|
Long Term Adverse Effects | 1 | 2015 | 10 | 0.130 |
Why?
|
Syncope | 1 | 2016 | 49 | 0.130 |
Why?
|
Blood Loss, Surgical | 2 | 2013 | 91 | 0.120 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 1020 | 0.120 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 103 | 0.120 |
Why?
|
Aortic Valve Insufficiency | 1 | 2015 | 47 | 0.120 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 359 | 0.120 |
Why?
|
Heart Valve Diseases | 2 | 2015 | 170 | 0.120 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 48 | 0.120 |
Why?
|
Metals | 1 | 2016 | 126 | 0.120 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2015 | 2 | 0.120 |
Why?
|
Injections | 3 | 2014 | 174 | 0.120 |
Why?
|
Elective Surgical Procedures | 2 | 2013 | 164 | 0.120 |
Why?
|
Education, Medical, Continuing | 2 | 2013 | 123 | 0.120 |
Why?
|
Vascular Grafting | 1 | 2015 | 13 | 0.120 |
Why?
|
Punctures | 3 | 2020 | 40 | 0.120 |
Why?
|
Computed Tomography Angiography | 1 | 2016 | 115 | 0.120 |
Why?
|
Ablation Techniques | 1 | 2015 | 31 | 0.120 |
Why?
|
Platelet Activation | 1 | 2015 | 85 | 0.120 |
Why?
|
Catheter Ablation | 1 | 2018 | 324 | 0.110 |
Why?
|
Clinical Decision-Making | 3 | 2024 | 311 | 0.110 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2015 | 57 | 0.110 |
Why?
|
Radiation Injuries | 1 | 2015 | 139 | 0.110 |
Why?
|
Delivery of Health Care | 2 | 2023 | 896 | 0.110 |
Why?
|
Thrombectomy | 2 | 2012 | 58 | 0.110 |
Why?
|
Quality Assurance, Health Care | 2 | 2020 | 319 | 0.110 |
Why?
|
Prosthesis Design | 2 | 2013 | 321 | 0.110 |
Why?
|
Warfarin | 1 | 2015 | 150 | 0.110 |
Why?
|
Therapy, Computer-Assisted | 1 | 2014 | 62 | 0.110 |
Why?
|
Creatine Kinase, MB Form | 1 | 2013 | 4 | 0.110 |
Why?
|
Pharmacogenetics | 1 | 2015 | 170 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2014 | 69 | 0.110 |
Why?
|
Academies and Institutes | 1 | 2013 | 47 | 0.110 |
Why?
|
Radiation | 1 | 2013 | 25 | 0.110 |
Why?
|
Renal Dialysis | 3 | 2014 | 417 | 0.110 |
Why?
|
Blood Vessel Prosthesis | 2 | 2006 | 125 | 0.110 |
Why?
|
Hemostasis, Surgical | 1 | 2013 | 19 | 0.110 |
Why?
|
Patient Selection | 5 | 2019 | 671 | 0.110 |
Why?
|
Health Services Accessibility | 1 | 2020 | 894 | 0.100 |
Why?
|
Cardiac Volume | 2 | 2003 | 12 | 0.100 |
Why?
|
Heparin | 2 | 2015 | 252 | 0.100 |
Why?
|
Adult | 18 | 2015 | 35361 | 0.100 |
Why?
|
Coronary Occlusion | 1 | 2012 | 19 | 0.100 |
Why?
|
Fibrinolytic Agents | 2 | 2009 | 264 | 0.100 |
Why?
|
Wound Closure Techniques | 1 | 2012 | 9 | 0.100 |
Why?
|
Coronary Artery Bypass, Off-Pump | 1 | 2012 | 16 | 0.100 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2015 | 255 | 0.100 |
Why?
|
Medical Audit | 1 | 2012 | 78 | 0.100 |
Why?
|
Tomography, Optical Coherence | 1 | 2013 | 179 | 0.100 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 1435 | 0.100 |
Why?
|
Embolism | 1 | 2012 | 44 | 0.100 |
Why?
|
Blood Platelets | 1 | 2015 | 369 | 0.100 |
Why?
|
Aneurysm, False | 1 | 2012 | 46 | 0.100 |
Why?
|
Quality of Life | 5 | 2019 | 2706 | 0.100 |
Why?
|
Angina, Unstable | 1 | 2012 | 77 | 0.100 |
Why?
|
Ambulatory Care | 1 | 2016 | 509 | 0.100 |
Why?
|
Triiodobenzoic Acids | 2 | 2011 | 11 | 0.090 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2012 | 75 | 0.090 |
Why?
|
Medication Adherence | 1 | 2016 | 571 | 0.090 |
Why?
|
Insurance Claim Review | 1 | 2012 | 74 | 0.090 |
Why?
|
Polyethylene Terephthalates | 1 | 1991 | 21 | 0.090 |
Why?
|
United States Department of Veterans Affairs | 2 | 2019 | 637 | 0.090 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 327 | 0.090 |
Why?
|
Phantoms, Imaging | 2 | 2002 | 139 | 0.090 |
Why?
|
Ventricular Function, Left | 1 | 2014 | 526 | 0.090 |
Why?
|
Manikins | 1 | 2010 | 23 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 861 | 0.080 |
Why?
|
Movement | 2 | 2009 | 269 | 0.080 |
Why?
|
Cardiovascular Agents | 4 | 2016 | 155 | 0.080 |
Why?
|
Sensitivity and Specificity | 4 | 2019 | 1840 | 0.080 |
Why?
|
Observer Variation | 3 | 2011 | 321 | 0.080 |
Why?
|
Recurrence | 4 | 2016 | 1013 | 0.080 |
Why?
|
Coronary Vessel Anomalies | 1 | 2009 | 32 | 0.080 |
Why?
|
Glomerular Filtration Rate | 3 | 2023 | 684 | 0.080 |
Why?
|
Prosthesis Failure | 1 | 2010 | 120 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2014 | 1504 | 0.080 |
Why?
|
Prevalence | 5 | 2019 | 2540 | 0.080 |
Why?
|
Equipment Failure | 2 | 2005 | 112 | 0.080 |
Why?
|
Cause of Death | 3 | 2020 | 392 | 0.080 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 1977 | 0.080 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 760 | 0.080 |
Why?
|
Vascular Closure Devices | 2 | 2020 | 6 | 0.080 |
Why?
|
Carotid Stenosis | 1 | 2009 | 85 | 0.080 |
Why?
|
Preoperative Period | 2 | 2021 | 112 | 0.070 |
Why?
|
Heart Atria | 6 | 1990 | 126 | 0.070 |
Why?
|
Liver Transplantation | 1 | 2015 | 800 | 0.070 |
Why?
|
Hyperbaric Oxygenation | 2 | 1998 | 40 | 0.070 |
Why?
|
Embolization, Therapeutic | 1 | 2010 | 209 | 0.070 |
Why?
|
Aftercare | 2 | 2022 | 206 | 0.070 |
Why?
|
Magnetic Resonance Angiography | 2 | 2009 | 237 | 0.070 |
Why?
|
Cardiac Output, Low | 1 | 2007 | 66 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 2530 | 0.070 |
Why?
|
Extremities | 1 | 2007 | 129 | 0.070 |
Why?
|
Mortality | 3 | 2016 | 310 | 0.070 |
Why?
|
Stroke Volume | 5 | 2015 | 587 | 0.070 |
Why?
|
Tissue Plasminogen Activator | 2 | 1998 | 225 | 0.060 |
Why?
|
Survival Analysis | 4 | 2013 | 1282 | 0.060 |
Why?
|
Hemodynamics | 3 | 2020 | 1095 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2006 | 88 | 0.060 |
Why?
|
Biomarkers | 4 | 2023 | 3874 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 5032 | 0.060 |
Why?
|
Lower Extremity | 1 | 2009 | 404 | 0.060 |
Why?
|
Systole | 2 | 1983 | 190 | 0.060 |
Why?
|
Sirolimus | 1 | 2006 | 194 | 0.060 |
Why?
|
Vascular Patency | 3 | 2012 | 102 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2024 | 72 | 0.060 |
Why?
|
Patient Safety | 2 | 2020 | 292 | 0.060 |
Why?
|
Intraoperative Complications | 2 | 2018 | 133 | 0.060 |
Why?
|
Equipment Safety | 1 | 2004 | 40 | 0.060 |
Why?
|
Prosthesis Implantation | 1 | 2006 | 149 | 0.060 |
Why?
|
Ventricular Fibrillation | 1 | 2024 | 58 | 0.060 |
Why?
|
Electric Countershock | 1 | 2005 | 105 | 0.060 |
Why?
|
Peptides | 1 | 2009 | 902 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 991 | 0.060 |
Why?
|
Intracranial Embolism | 1 | 2024 | 32 | 0.060 |
Why?
|
Protective Factors | 1 | 2024 | 90 | 0.060 |
Why?
|
Adenosine | 2 | 2016 | 213 | 0.060 |
Why?
|
Reoperation | 2 | 2021 | 555 | 0.060 |
Why?
|
Risk | 3 | 2012 | 866 | 0.060 |
Why?
|
Prosthesis-Related Infections | 1 | 2005 | 80 | 0.060 |
Why?
|
Blood Vessel Prosthesis Implantation | 2 | 2004 | 200 | 0.050 |
Why?
|
United States Food and Drug Administration | 2 | 2016 | 204 | 0.050 |
Why?
|
Patient Preference | 2 | 2016 | 182 | 0.050 |
Why?
|
Catheters | 1 | 2023 | 67 | 0.050 |
Why?
|
Troponin | 1 | 2023 | 50 | 0.050 |
Why?
|
Pyridines | 1 | 2006 | 472 | 0.050 |
Why?
|
Disability Evaluation | 1 | 2024 | 290 | 0.050 |
Why?
|
Kidney | 2 | 2023 | 1330 | 0.050 |
Why?
|
Mass Screening | 1 | 2009 | 1121 | 0.050 |
Why?
|
Risk Adjustment | 2 | 2013 | 78 | 0.050 |
Why?
|
Diagnosis-Related Groups | 1 | 2021 | 28 | 0.050 |
Why?
|
Curriculum | 1 | 2008 | 925 | 0.050 |
Why?
|
Physical Exertion | 1 | 1982 | 215 | 0.050 |
Why?
|
Patient Participation | 1 | 2024 | 402 | 0.050 |
Why?
|
Endocardium | 2 | 1990 | 32 | 0.040 |
Why?
|
Myocardial Contraction | 1 | 1982 | 336 | 0.040 |
Why?
|
Costs and Cost Analysis | 2 | 2019 | 211 | 0.040 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 112 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 94 | 0.040 |
Why?
|
Florida | 1 | 2020 | 91 | 0.040 |
Why?
|
Pressure | 2 | 2012 | 238 | 0.040 |
Why?
|
Matched-Pair Analysis | 1 | 2020 | 44 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2021 | 124 | 0.040 |
Why?
|
Population Density | 1 | 2020 | 93 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 207 | 0.040 |
Why?
|
Models, Statistical | 2 | 2014 | 626 | 0.040 |
Why?
|
Heart Rate | 4 | 2011 | 807 | 0.040 |
Why?
|
Tachycardia, Supraventricular | 2 | 1990 | 44 | 0.040 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2003 | 387 | 0.040 |
Why?
|
Travel | 1 | 2020 | 123 | 0.040 |
Why?
|
Device Approval | 1 | 2019 | 21 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2012 | 1213 | 0.040 |
Why?
|
Organizational Innovation | 1 | 2020 | 139 | 0.040 |
Why?
|
Anatomic Landmarks | 1 | 2019 | 28 | 0.040 |
Why?
|
Patient-Specific Modeling | 1 | 2019 | 39 | 0.040 |
Why?
|
Hospitals, University | 1 | 2019 | 177 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2019 | 133 | 0.040 |
Why?
|
Writing | 1 | 2020 | 92 | 0.040 |
Why?
|
Colorado | 3 | 2019 | 4443 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2012 | 615 | 0.040 |
Why?
|
Plasminogen Activators | 1 | 1997 | 7 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2020 | 326 | 0.040 |
Why?
|
Social Media | 1 | 2020 | 144 | 0.040 |
Why?
|
Data Collection | 1 | 2020 | 652 | 0.030 |
Why?
|
Pulmonary Artery | 1 | 2023 | 1091 | 0.030 |
Why?
|
Exercise Test | 3 | 2014 | 619 | 0.030 |
Why?
|
Adenosine Diphosphate | 1 | 2016 | 78 | 0.030 |
Why?
|
Disease Management | 1 | 2020 | 594 | 0.030 |
Why?
|
Automation | 1 | 2016 | 81 | 0.030 |
Why?
|
Radiologic Health | 1 | 2015 | 5 | 0.030 |
Why?
|
Technology Assessment, Biomedical | 1 | 2015 | 31 | 0.030 |
Why?
|
Radiation Exposure | 1 | 2016 | 48 | 0.030 |
Why?
|
Netherlands | 1 | 2015 | 77 | 0.030 |
Why?
|
Drug Costs | 1 | 2016 | 110 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2016 | 117 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 729 | 0.030 |
Why?
|
Platelet Function Tests | 1 | 2015 | 25 | 0.030 |
Why?
|
Single-Blind Method | 2 | 2007 | 273 | 0.030 |
Why?
|
Health Expenditures | 1 | 2016 | 187 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2014 | 15 | 0.030 |
Why?
|
Radiology, Interventional | 1 | 1994 | 31 | 0.030 |
Why?
|
Thrombelastography | 1 | 2015 | 148 | 0.030 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2015 | 41 | 0.030 |
Why?
|
Patient Admission | 1 | 2016 | 185 | 0.030 |
Why?
|
Echocardiography, Stress | 1 | 2014 | 21 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2015 | 255 | 0.030 |
Why?
|
Hospital Costs | 1 | 2015 | 117 | 0.030 |
Why?
|
Angina, Stable | 1 | 2014 | 17 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2014 | 36 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 1002 | 0.030 |
Why?
|
Virginia | 1 | 2013 | 59 | 0.030 |
Why?
|
Atrial Function | 2 | 1990 | 11 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2013 | 175 | 0.030 |
Why?
|
Solvents | 1 | 2014 | 107 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
Echocardiography | 2 | 2014 | 634 | 0.030 |
Why?
|
Professional Competence | 1 | 2014 | 94 | 0.030 |
Why?
|
Administration, Oral | 1 | 2015 | 783 | 0.030 |
Why?
|
Foundations | 1 | 2013 | 24 | 0.030 |
Why?
|
Canada | 1 | 2014 | 355 | 0.030 |
Why?
|
Cladribine | 1 | 1993 | 1 | 0.030 |
Why?
|
Sinoatrial Node | 2 | 1990 | 28 | 0.030 |
Why?
|
Blood Pressure | 3 | 2011 | 1743 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2015 | 253 | 0.030 |
Why?
|
Research Report | 1 | 2013 | 76 | 0.030 |
Why?
|
Telemetry | 2 | 1989 | 39 | 0.030 |
Why?
|
Observation | 1 | 2012 | 52 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1993 | 78 | 0.020 |
Why?
|
Linear Models | 1 | 2014 | 817 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 318 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2012 | 306 | 0.020 |
Why?
|
Posture | 2 | 2009 | 174 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 1968 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 1993 | 120 | 0.020 |
Why?
|
Software | 1 | 2016 | 611 | 0.020 |
Why?
|
Pectoralis Muscles | 1 | 1991 | 17 | 0.020 |
Why?
|
Esthetics | 1 | 1991 | 50 | 0.020 |
Why?
|
Psychomotor Agitation | 1 | 1991 | 65 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 376 | 0.020 |
Why?
|
Sex Distribution | 1 | 2011 | 357 | 0.020 |
Why?
|
Consumer Behavior | 1 | 1991 | 71 | 0.020 |
Why?
|
Leukemia | 1 | 1993 | 228 | 0.020 |
Why?
|
Automation, Laboratory | 1 | 2010 | 7 | 0.020 |
Why?
|
Suture Techniques | 1 | 1991 | 120 | 0.020 |
Why?
|
X-Rays | 1 | 2010 | 32 | 0.020 |
Why?
|
Tachycardia, Paroxysmal | 1 | 1989 | 7 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2012 | 560 | 0.020 |
Why?
|
Torsion, Mechanical | 1 | 2009 | 6 | 0.020 |
Why?
|
Contraindications | 1 | 2009 | 90 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2007 | 859 | 0.020 |
Why?
|
Hospitals, Veterans | 1 | 2011 | 264 | 0.020 |
Why?
|
Graft Survival | 1 | 2012 | 523 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2011 | 320 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2011 | 253 | 0.020 |
Why?
|
Medication Errors | 1 | 2009 | 96 | 0.020 |
Why?
|
Drug Utilization | 1 | 2009 | 169 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2010 | 163 | 0.020 |
Why?
|
Calibration | 1 | 2009 | 137 | 0.020 |
Why?
|
Europe | 1 | 2009 | 366 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2019 | 5704 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2003 | 1858 | 0.020 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2007 | 43 | 0.020 |
Why?
|
Regression Analysis | 1 | 2009 | 987 | 0.020 |
Why?
|
Veins | 1 | 2007 | 60 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 421 | 0.020 |
Why?
|
Pain Measurement | 1 | 2009 | 489 | 0.020 |
Why?
|
Wound Healing | 1 | 2009 | 308 | 0.020 |
Why?
|
Life Tables | 1 | 2006 | 18 | 0.020 |
Why?
|
Biomechanical Phenomena | 1 | 2009 | 784 | 0.020 |
Why?
|
Coronary Circulation | 1 | 1986 | 138 | 0.020 |
Why?
|
Drug Implants | 1 | 2006 | 82 | 0.020 |
Why?
|
Program Evaluation | 1 | 2010 | 868 | 0.020 |
Why?
|
Pattern Recognition, Automated | 1 | 2006 | 73 | 0.020 |
Why?
|
Artifacts | 1 | 2006 | 124 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2007 | 462 | 0.020 |
Why?
|
Aorta | 1 | 2007 | 410 | 0.010 |
Why?
|
Hospitalization | 2 | 2006 | 2080 | 0.010 |
Why?
|
Acute Disease | 1 | 2007 | 978 | 0.010 |
Why?
|
Probability | 1 | 2005 | 313 | 0.010 |
Why?
|
Streptokinase | 2 | 1998 | 10 | 0.010 |
Why?
|
Diabetes Insipidus | 1 | 1983 | 7 | 0.010 |
Why?
|
Whole-Body Irradiation | 1 | 2004 | 76 | 0.010 |
Why?
|
Critical Illness | 1 | 2009 | 753 | 0.010 |
Why?
|
Pain | 1 | 2009 | 761 | 0.010 |
Why?
|
Sound | 1 | 1983 | 67 | 0.010 |
Why?
|
Technology | 1 | 1983 | 83 | 0.010 |
Why?
|
Heart Function Tests | 1 | 2003 | 61 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2006 | 233 | 0.010 |
Why?
|
Echocardiography, Doppler | 1 | 2003 | 111 | 0.010 |
Why?
|
Aging | 1 | 2012 | 1767 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 3348 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2006 | 734 | 0.010 |
Why?
|
Exercise Tolerance | 1 | 2002 | 266 | 0.010 |
Why?
|
Stress, Mechanical | 1 | 2002 | 470 | 0.010 |
Why?
|
Exercise | 1 | 1989 | 1923 | 0.010 |
Why?
|
Ultrasonography | 1 | 2001 | 727 | 0.010 |
Why?
|
Creatine Kinase | 1 | 1997 | 77 | 0.010 |
Why?
|
Chronic Disease | 1 | 2003 | 1715 | 0.010 |
Why?
|
Safety | 1 | 1998 | 325 | 0.010 |
Why?
|
Subclavian Vein | 1 | 1994 | 15 | 0.010 |
Why?
|
Traction | 1 | 1994 | 19 | 0.010 |
Why?
|
Femoral Vein | 1 | 1994 | 31 | 0.010 |
Why?
|
Staphylococcus epidermidis | 1 | 1994 | 76 | 0.010 |
Why?
|
Steroids | 1 | 1994 | 148 | 0.010 |
Why?
|
Cytarabine | 1 | 1993 | 54 | 0.010 |
Why?
|
Adolescent | 3 | 1998 | 20197 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1993 | 63 | 0.010 |
Why?
|
Vincristine | 1 | 1993 | 109 | 0.010 |
Why?
|
Pilot Projects | 1 | 1997 | 1545 | 0.010 |
Why?
|
Drug Resistance | 1 | 1993 | 166 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 1993 | 195 | 0.010 |
Why?
|
Doxorubicin | 1 | 1993 | 319 | 0.010 |
Why?
|
Atrioventricular Node | 1 | 1990 | 14 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1993 | 928 | 0.010 |
Why?
|
Body Constitution | 1 | 1990 | 53 | 0.010 |
Why?
|
Dizziness | 1 | 1990 | 80 | 0.010 |
Why?
|
Respiration | 1 | 1990 | 191 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 1994 | 385 | 0.010 |
Why?
|
Syndrome | 1 | 1990 | 342 | 0.010 |
Why?
|
Cardiac Complexes, Premature | 1 | 1988 | 2 | 0.000 |
Why?
|
Refractory Period, Electrophysiological | 1 | 1988 | 5 | 0.000 |
Why?
|
Dyspnea | 1 | 1990 | 236 | 0.000 |
Why?
|
Fatigue | 1 | 1990 | 319 | 0.000 |
Why?
|
Tromethamine | 1 | 1986 | 2 | 0.000 |
Why?
|
Potassium Chloride | 1 | 1986 | 34 | 0.000 |
Why?
|
Citrates | 1 | 1986 | 42 | 0.000 |
Why?
|
Heart Arrest, Induced | 1 | 1986 | 31 | 0.000 |
Why?
|
Protein Binding | 1 | 1993 | 2086 | 0.000 |
Why?
|
Citric Acid | 1 | 1986 | 30 | 0.000 |
Why?
|
Glutamates | 1 | 1986 | 58 | 0.000 |
Why?
|
Aspartic Acid | 1 | 1986 | 79 | 0.000 |
Why?
|
Phosphates | 1 | 1986 | 168 | 0.000 |
Why?
|
Glutamic Acid | 1 | 1986 | 227 | 0.000 |
Why?
|
Diuresis | 1 | 1983 | 10 | 0.000 |
Why?
|
Arginine Vasopressin | 1 | 1983 | 42 | 0.000 |
Why?
|
Anxiety | 1 | 1990 | 947 | 0.000 |
Why?
|
Vasopressins | 1 | 1983 | 64 | 0.000 |
Why?
|
Heart | 1 | 1986 | 650 | 0.000 |
Why?
|
Glucose | 1 | 1986 | 976 | 0.000 |
Why?
|
Surveys and Questionnaires | 1 | 1990 | 5355 | 0.000 |
Why?
|